Affirm: Ignore The 'Ludicrous' $1.6 Billion, Own The Real Story

Affirm reported GAAP EPS of $4.62, but management emphasized it benefited from a one-time tax allowance release rather than core earnings. On the operating side, AFRM delivered 33% revenue growth, 36% GMV growth, and a 49% increase in adjusted operating income, with margins expanding on improved performance. Credit performance stayed stable and funding costs fell 103 bps to 5.8%, supporting the profitability and margin expansion.

Analysis

The market should look past the headline EPS and focus on the fact that AFRM is showing a cleaner operating leverage story: higher transaction volume is now being monetized while funding costs are easing, which is the right mix for equity durability. That matters because BNPL economics are usually crushed by spread volatility; a 103 bp decline in funding costs is not just a margin tailwind, it improves the viability of longer-duration lending and reduces the need to sacrifice growth for profitability.

Competitive implications are more interesting than the print itself. If AFRM can keep lowering its cost of capital, it can price more aggressively versus PYPL and any wallet-linked BNPL offers without giving up unit economics, and that raises the bar for newcomers that rely on cheaper customer acquisition rather than underwriting discipline. The second-order winner is likely the ABS and fintech credit complex: tighter securitization spreads can widen the investment window for consumer finance, while a weaker funding backdrop would quickly re-rate the space in reverse.

The main risk is that investors extrapolate a near-term funding tailwind into a structural one. If consumer credit softens over the next 1-2 quarters, or if the ABS market widens, AFRM's margin expansion can stall quickly; that would matter more than revenue growth because the stock is likely to be valued on forward contribution margin and credit loss assumptions, not reported GAAP earnings. A reversal would also come from management guiding conservatively on take-rate or charge-offs, which would signal this is cyclical benefit rather than durable operating improvement.

Contrarian view: the market may still be underestimating how much of AFRM's value is tied to the cost of capital rather than headline growth. If funding remains constructive for another 6-12 months, the equity can compound faster than consensus expects because every incremental dollar of GMV becomes more profitable; if not, the move is probably a trap and should be faded on any spread widening or credit surprise.

Key Decisions for Investors

• Long AFRM on pullbacks over the next 1-3 weeks; use the print to build a position only if the stock holds above post-earnings support and management does not soften guidance. Upside comes from multiple expansion if margin gains persist; invalidate if funding costs re-widen or credit metrics deteriorate next quarter.
• Pair trade: long AFRM / short PYPL for 1-3 months to express the view that BNPL-specific operating leverage is being rewarded more than legacy payments scale. This works best if AFRM re-rates on margin expansion while PYPL remains tied to slower growth and less visible credit leverage.
• Monitor consumer credit ABS spreads as the key macro hedge; if AAA consumer ABS widens meaningfully, reduce AFRM exposure immediately. The thesis is most fragile if securitization pricing moves against fintech lenders before the next earnings cycle.
• Consider AFRM call spreads into the next catalyst window rather than outright equity if you want convexity with defined risk. This is best if the stock has not yet fully reflected lower funding costs, but it should be cut if charge-offs or guidance reset higher.